The incidence of renal\related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active\ and placebo\controlled trials (N?=?5598) and in a 104\week research vs glimepiride (N?=?1450) was low and…